Evidence map›Paper›PMID 28343305›Full record

ReviewVirchows Archiv : an international journal of pathology2017

Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature.

Alireza Salem, Diana Bell, Boris Sepesi, Vassiliki Papadimitrakopoulou, Adel El-Naggar, Cesar A Moran, Neda Kalhor

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03976518 (Phase II, Open-label Study of Atezolizumab in a Cohort of Pretreated, Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03976518 phase2completednot on this mapstarted 2019, after this paper: background citation

Phase II, Open-label Study of Atezolizumab in a Cohort of Pretreated, Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Rare Histological Subtypes (CHANCE Trial).

TypeinterventionalSponsorGruppo Oncologico Italiano di Ricerca ClinicaRan2019 to 2024Enrolled43ConditionsNon-Small Cell Lung CancerArmsAtezolizumab
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Problematic breast tumors reassessed in light of novel molecular data.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Review
  13. Article
  14. Review
  15. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019
    Article
  16. Immunohistochemical Assessment of BAP1 Protein in Mucoepidermoid Carcinomas.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2019
    Article
  17. Article
  18. Article
  19. Primary mucoepidermoid carcinoma of the lung with prominent clear cells.Proceedings (Baylor University. Medical Center) · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alireza SalemDepartment of Pathology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0085, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-5492-1962
Diana BellDepartment of Pathology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0085, Houston, TX, 77030, USA.
Boris SepesiDepartment of Surgery, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0085, Houston, TX, 77030, USA.
Vassiliki PapadimitrakopoulouDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0085, Houston, TX, 77030, USA.
Adel El-NaggarDepartment of Pathology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0085, Houston, TX, 77030, USA.
Cesar A MoranDepartment of Pathology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0085, Houston, TX, 77030, USA.
Neda KalhorDepartment of Pathology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0085, Houston, TX, 77030, USA. nkalhor@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary bronchopulmonary mucoepidermoid carcinoma (BPMEC) is a rare tumor. The fusion protein MECT1-MAML2 has been implicated as a causative genetic event in salivary and BPMECs. Several studies have shown the impact of MECT1-MAML2 on the diagnosis and prognosis of salivary gland mucoepidermoid carcinoma; however, few studies have been published regarding MECT1-MAML2 in the context of primary BPMEC. We describe the clinicopathologic, genetic, and outcome data of 16 patients with BPMEC. Clinicopathologic features were recorded from the electronic medical records. All tumors were reviewed by two expert pulmonary pathologists and graded according to previously established criteria. The presence of MECT1-MAML2 was evaluated with reverse transcription polymerase chain reaction using RNA extracted from formalin-fixed paraffin-embedded tumor tissue. Patients included 9 women and 7 men with a median age of 50 years (range, 7 to 82 years). Tumors exhibited low (n = 14, 88%), and high (n = 2, 12%) grade histologic features. Eight of nine tested tumors (89%) were positive for MECT1-MAML2. The median follow-up time was 40.8 months (range, 1.8-120). Median overall survival for patients with high-grade tumors was 12 months, which was significantly (p = 0.002) shorter than that for patients with low-grade tumors (survival undefined). We also provide a comprehensive review of literature of cases of primary bronchopulmonary mucoepidermoid carcinoma and summarize our findings in this context. MECT1-MAML2 fusion transcript is a driver genetic event in the pathogenesis of primary BPMEC. Histologic grade continues to play a pivotal role in the survival of patients with primary bronchopulmonary mucoepidermoid carcinoma.

Indexed as

AdolescentAdultAgedAged, 80 and overCarcinoma, MucoepidermoidChildFemaleHumansLung NeoplasmsMaleMiddle AgedOncogene Proteins, FusionReverse Transcriptase Polymerase Chain ReactionYoung AdultMECT1-MAML2 fusion protein, humanOncogene Proteins, FusionClinicopathologicGeneticHistologic gradeMECT1-MAML2Primary bronchopulmonary mucoepidermoid carcinomaSalivary gland-type tumor

Identifiers

PMID28343305
OpenAlexW2603278873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.